-+ 0.00%
-+ 0.00%
-+ 0.00%

Azitra posts ex vivo anti-wrinkle, repeat-dose distribution gains for ATR-COSF program

PUBT·07/15/2026 14:11:05
Listen to the news
Azitra posts ex vivo anti-wrinkle, repeat-dose distribution gains for ATR-COSF program
  • Azitra reported ex vivo repeat-dose results for its ATR-COSF cosmetic program showing increased delivery of rHDfilaggrin into deeper skin layers.
  • A 2% lyophilized supernatant hydrogel showed greater distribution into the stratum granulosum versus prior single-dose work.
  • Elasticity rose dose-dependently at 20 hours, ranging from 1.6x at 0.09% w/w to 4.4x at 7.5% w/w.
  • Azitra plans additional ex vivo wrinkle-model testing ahead of a human study aimed at visible wrinkle-reduction outcomes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607151010PR_NEWS_USPR_____NY05259) on July 15, 2026, and is solely responsible for the information contained therein.